Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed (clinically) with type 2 diabetes mellitus (T2D) for at least 1 year prior to screening.~* Have been treated with basal-bolus multiple daily injection (MDI) therapy for at least 90 days prior to screening including:~  * Basal insulin glargine U-100, in combination with bolus insulin analog (insulin lispro, insulin aspart, or insulin glulisine) with meals.~ * Participant must have been treated with the same type of allowed bolus insulin analog for at least 30 days prior to screening.~* Participants may be treated with up to 3 of the following oral antihyperglycemic medications (OAMs) for T2D in accordance with local regulations:~  1. Metformin~ 2. Dipeptidyl peptidase-4 (DPP-4) inhibitor~ 3. sodium glucose cotransporter 2 (SGLT2) inhibitor~ 4. oral glucagon-like peptide 1 (GLP-1) agonist~* Doses of OAMs are required to have been stable for at least 90 days prior to screening.~* Participants may be treated with injectable GLP-1 receptor agonist for T2D in accordance with local regulations. The GLP-1 receptor agonist dose is required to have been stable for at least 90 days prior to screening.~* Have an HbA1c value ≥7.5% and ≤10% according to the central laboratory at screening.~Exclusion Criteria:~* Have been diagnosed at any time with type 1 diabetes mellitus or latent autoimmune diabetes in adults.~* Have had any episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within 6 months prior to screening.~* Have had any episode of hyperglycemic hyperosmolar state or diabetic ketoacidosis within 6 months prior to screening.~* Have hypoglycemia unawareness as judged by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY900014 (Type: EXPERIMENTAL): LY900014 (100 units/milliliter (U/mL)) is a mealtime insulin administered subcutaneously (SC) 0-2 minutes prior to each meal in combination with insulin glargine (100 U/mL) SC as long-acting insulin. Mealtime (bolus) and long-acting (basal) insulin doses were titrated to achieve glucose targets during the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).